Please visit our MS learning channel on YouTube, which provides hundreds of MS related topics from many of our video recorded education programs and archived here: -- Be empowered with MS views and news. Opt-in with us:

~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Thursday, April 20, 2017

No Evidence of Disease Activity Achieved in Multiple Sclerosis with Dimethyl Fumarate

Click here to receive MS news via e-mail

Post hoc data analysis of the DEFINE and CONFIRM trials showed that a higher percentage of patients with relapsing-remitting multiple sclerosis (RRMS) achieved no evidence of disease activity (NEDA) with delayed-release dimethyl fumarate (DMF) compared with placebo. The results were published in the European Journal of Neurology.1
NEDA is a relatively new composite outcome that is being used more often to measure therapeutic response in multiple sclerosis. NEDA is comprised of 3 factors: no clinical relapse, no disability progression measured by the Expanded Disability Status Scale (EDSS) for 12 weeks, and no evidence of disease activity on magnetic resonance imaging (MRI).

MS Views and News
Providing educational information, resources and services for those affected by MS, globally
MS Views and News is MAKING an IMPACT on those affected by Multiple Sclerosis

No comments: